T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy
- 21 March 2023
- journal article
- editorial
- Published by Elsevier in Trends in Immunology
- Vol. 44 (6) , 397-398
Abstract
No abstract availableKeywords
Funding Information
- Stand Up To Cancer
- National Institutes of Health (R01CA237311)
- American Lebanese Syrian Associated Charities
- National Comprehensive Cancer Network
- Assisi Foundation of Memphis
- Alex's Lemonade Stand Foundation for Childhood Cancer
This publication has 11 references indexed in Scilit:
- Functional T cells are capable of supernumerary cell division and longevityNature, 2023
- CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomasNature Communications, 2022
- cBAF complex components and MYC cooperate early in CD8+ T cell fateNature, 2022
- Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activityScience Translational Medicine, 2021
- CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemiaCell Reports, 2021
- BATF3 programs CD8+ T cell memoryNature Immunology, 2020
- Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/LymphomaCancer Cell, 2018
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsNature, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2018